Sue Myers
Optometrist · Opelousas, LANPI 1083601280
Payments from drug & device makers
Across 73 payments — averaging $50.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$474
- AbbVie$383
- Biotissue Holdings Inc.$355
- Johnson & Johnson Surgical Vision, Inc.$275
- Sun Pharmaceutical Industries Inc.$275
- Glaukos Corporation$263
- plus $2K from 11 others
What the payments were for
- Food & beverage$3,680100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 6 | $474 |
| AbbVie(2 entities) | 13 | $383 |
| Biotissue Holdings Inc. | 4 | $355 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $275 |
| Sun Pharmaceutical Industries Inc. | 6 | $275 |
| Glaukos Corporation | 2 | $263 |
| Regeneron Healthcare Solutions, Inc. | 2 | $250 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $250 |
| Bausch & Lomb Americas Inc. | 4 | $248 |
| Mallinckrodt Hospital Products Inc. | 2 | $224 |
| Tarsus Pharmaceuticals, Inc. | 9 | $213 |
| Ocular Therapeutix, Inc. | 1 | $117 |
| Novartis | 6 | $105 |
| Shire North American Group Inc | 2 | $79 |
| Dompe US, Inc. | 3 | $77 |
| Aerie Pharmaceuticals, Inc. | 4 | $63 |
| Oyster Point Pharma, Inc. | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$250
- ACTHAR$224
- KXL System$151
- Photrexa$151
- AcrySof IQ VIVITY$137
- CEQUA$129
- BROMSITE$129
- XELPROS$129
- MIEBO$125
- XIIDRA$125
- TRYPTYR$120
- DEXTENZA$117
- Photrexa Viscous and Photrexa$111
- VUITY$109
- XDEMVY$103
- Hydrus Microstent$100
- Voyager DSLT$100
How this compares
$3,680 in reported general payments places this provider in the 75th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 144 | $91,016 |
| XdemvyLotilaner | 28 | $52,612 |
| LumiganBimatoprost | 54 | $28,424 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 105 | $23,661 |
| XiidraLifitegrast | 29 | $20,632 |
| Latanoprost | 2,698 | $18,285 |
| Brimonidine Tartrate | 460 | $15,938 |
| CombiganBrimonidine Tartrate/Timolol | 50 | $15,161 |
| RhopressaNetarsudil Mesylate | 36 | $12,115 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 759 | $11,959 |
| RocklatanNetarsudil Mesylat/Latanoprost | 31 | $10,422 |
| Restasis MultidoseCyclosporine | 12 | $7,634 |
| Timolol Maleate | 476 | $7,558 |
| Brinzolamide | 39 | $6,550 |
| Cyclosporine | 23 | $5,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose | $383 | $142,235260 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $213 | $52,61228 claims |
| AlconSimbrinza | $474 | $23,661105 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $63 | $22,53767 claims |
| Bausch & Lomb Americas Inc.Xiidra | $248 | $20,63229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Opelousas
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- Stephen LewisShreveport$37K
- John McCallLogansport$32K
- Jason AllemondZachary$26K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.